ALPMY — Astellas Pharma, Inc.

Is ALPMY overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - General

Oversold As of October 3, 2026

Astellas Pharma, Inc. (ALPMY) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Drug Manufacturers - General) last closed at $14.32. The rating moved from Neutral to Oversold on September 30, 2026.

See all oversold Healthcare stocks →

AI analysis

Astellas Pharma, Inc. (ALPMY) is a diversified specialty pharmaceutical company with established oncology and specialty-care franchises and a late-stage biologics pipeline that provides medium‑term growth optionality. The firm’s global footprint and historically steady cash generation support investment in R&D and selective M&A, but the shares are sensitive to policy-driven pricing pressure, patent cliffs, and competitive dynamics (notably evolving metabolic and specialty therapy competition). Near-term market tone is cautious and volumes light, limiting conviction for a strong directional move absent clear clinical, regulatory, or policy catalysts. Monitor upcoming clinical readouts, any material regulatory decisions, and payer policy developments for directional impact.

Key factors

  • Diversified product portfolio with established oncology and specialty-care franchises that generate steady cash flow
  • Meaningful late‑stage pipeline and partnerships that support medium‑term growth and optionality in biologics/specialty segments
  • Global commercial footprint (Japan, U.S., EMEA) that provides revenue diversification but also FX exposure
  • Disciplined capital allocation history (R&D spend, M&A focus, shareholder returns) supporting long‑term shareholder value
  • Defensive characteristics in a risk‑off market: exposure to essential medicines and specialty therapies tends to attract flows in uncertain environments

Risks

  • Heightened payer and policy pressure (U.S. Medicare negotiation / IRA effects) that could compress pricing and access for higher‑cost products
  • Patent expirations and generic competition risk for key products, which could materially reduce revenue if not offset by new launches
  • Competitive pressure from next‑generation therapies (including GLP‑1/amylin combinations in metabolic space and new entrants in oncology) that may erode share or pricing power
  • Clinical or regulatory setbacks in late‑stage programs that would reduce pipeline value and near‑term upside
  • Foreign exchange volatility and supply‑chain disruptions given sizable international operations
  • Geopolitical risk and macro risk‑off flows that can depress ADR/OTC liquidity and valuation multiples

See today's live rating, score and targets

Members see the live hourly rating for ALPMY — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.